Filing Analysis: Holowesko Partners LTD Lifted Its Astrazeneca Plc (AZN) Stake by $5.73 Million

Filing Analysis: Holowesko Partners LTD Lifted Its Astrazeneca Plc (AZN) Stake by $5.73 Million

Holowesko Partners Ltd increased its stake in Astrazeneca Plc (AZN) by 5.88% based on its latest 2016Q3 regulatory filing with the SEC. Holowesko Partners Ltd bought 179,000 shares as the company’s stock rose 8.02% with the market. The hedge fund held 3.22 million shares of the major pharmaceuticals company at the end of 2016Q3, valued at $105.84 million, up from 3.04M at the end of the previous reported quarter. Holowesko Partners Ltd who had been investing in Astrazeneca Plc for a number of months, seems to be bullish on the $70.66B market cap company. The stock is down 2.16% or $0.62 hitting $28.12, despite the positive news. About 3.23M shares traded hands. AstraZeneca plc (ADR) (NYSE:AZN) has declined 3.69% since June 7, 2016 and is downtrending. It has underperformed by 11.11% the S&P500.

Holowesko Partners Ltd is a Bahamas-based hedge fund with more than $4.09 billion AUM in March, 2014. This fund invests only a small percentage of its assets in equities and options. Taken from Holowesko Partners latest Adv, the fund reported to have 15 full and part-time employees. Among which 15 performing investment advisory and research functions. The hedge fund had between 1-10 clients.

More news for AstraZeneca plc (ADR) (NYSE:AZN) were recently published by:, which released: “AstraZeneca plc (ADR): What Are the Future Prospects?” on August 01, 2016.‘s article titled: “3 Big Stock Charts: Chesapeake Energy Corporation (CHK), AstraZeneca plc (ADR …” and published on October 07, 2016 is yet another important article.

According to Zacks Investment Research, “AstraZeneca PLC is one of the top five pharmaceutical companies in the world based on sales and is a therapeutic leader in cardiovascular, gastrointestinal, oncology, anesthesia including pain management, central nervous system (CNS) and respiratory products. They are engaged in the research, development, manufacture and marketing of ethical (prescription) pharmaceuticals and agricultural products, and the supply of healthcare services.”

AstraZeneca plc (ADR) (NYSE:AZN) Ratings Coverage

Out of 18 analysts covering AstraZeneca plc (ADR) (NYSE:AZN), 13 rate it a “Buy”, 1 “Sell”, while 4 “Hold”. This means 72% are positive. AstraZeneca plc (ADR) has been the topic of 22 analyst reports since July 31, 2015 according to StockzIntelligence Inc. The firm has “Overweight” rating by Piperjaffray given on Friday, September 23. As per Tuesday, January 19, the company rating was upgraded by Barclays Capital. HSBC upgraded the shares of AZN in a report on Wednesday, September 2 to “Buy” rating. The company was maintained on Monday, May 2 by Leerink Swann. The stock has “Hold” rating given by Jefferies on Tuesday, March 15. The stock of AstraZeneca plc (ADR) (NYSE:AZN) has “Neutral” rating given on Wednesday, September 14 by BNP Paribas. The firm earned “Hold” rating on Monday, November 2 by Nordea. The rating was upgraded by Leerink Swann to “Outperform” on Friday, December 9. The stock of AstraZeneca plc (ADR) (NYSE:AZN) earned “Buy” rating by Deutsche Bank on Monday, September 14. The rating was upgraded by Morgan Stanley to “Overweight” on Tuesday, December 1.

AZN Company Profile

AstraZeneca PLC (AstraZeneca), incorporated on June 17, 1992, is a biopharmaceutical company. The Firm focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas. The Firm has its activities in over 100 countries. The Company’s pipeline includes over 150 projects of which approximately 125 are in the clinical phase of development.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Leave a Reply

Be the First to Comment!

Notify of